A Phase 3 study funded by Pfizer Inc. (NYSE: PFE) suggests that a nucleoside-modified messenger RNA influenza vaccine could offer stronger protection than traditional flu shots, marking a potential ...
Pfizer’s mRNA flu vaccine outperformed the standard flu shot in a Phase 3 clinical trial, according to results published Wednesday in the New England Journal of Medicine. The vaccine uses the same ...
Pfizer's mRNA flu vaccine worked better than a standard flu shot in a large Phase 3 trial, researchers reported. The results, published Nov. 19 in The New England Journal of Medicine, suggest that ...
Pfizer’s mRNA flu shot prevented more flu-like illness than a standard vaccine More than 18,000 adults took part in the study Side effects were mild and went away quickly FRIDAY, Nov. 21, 2025 ...
FRIDAY, Nov. 21, 2025 (HealthDay News) — Pfizer’s mRNA flu vaccine worked better than a standard flu shot in a large Phase 3 trial, researchers reported. The results, published Nov. 19 in The New ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results